Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
240 hedge funds and large institutions have $3.5B invested in Akero Therapeutics in 2025 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 92 increasing their positions, 49 reducing their positions, and 26 closing their positions.
192% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 26
88% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 49
70% more capital invested
Capital invested by funds: $2.06B → $3.5B (+$1.44B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
40% more call options, than puts
Call options by funds: $51.2M | Put options by funds: $36.6M
26% more funds holding
Funds holding: 191 → 240 (+49)
2.28% more ownership
Funds ownership: 106.28% → 108.56% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$75.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$72.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$56.5M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$53M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$43.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$24.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$23.2M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$18.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.1M |
AKRO Hedge Fund Activity: Q1 2025 in Review
240 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2025, worth a combined $3.5B — up 70% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new AKRO positions and 26 closed out — a net gain of 50 holders — while 92 added to existing stakes and 49 trimmed.
The largest buyer was UBS Group, adding an estimated $75.6M. The largest seller was Wellington Management Group, cutting an estimated $61.1M.
- 240 institutional investors held Akero Therapeutics (AKRO) as of Q1 2025, up from 191 in Q4 2024.
- Funds reported $3.5B of Akero Therapeutics stock for Q1 2025, up 70% quarter-over-quarter.
- 76 funds opened new Akero Therapeutics positions in Q1 2025 and 26 closed out, a net change of +50 holders.
- The largest Akero Therapeutics buyer in Q1 2025 was UBS Group, an estimated $75.6M added.
- The largest Akero Therapeutics seller in Q1 2025 was Wellington Management Group, an estimated $61.1M sold.
Based on aggregated 13F filings for Q1 2025.